Health Canada has issued a Notice of Compliance to Lundbeck Canada Inc., for the drug product Treanda. Treanda contains the medicinal ingredient bendamustine hydrochloride (HCl) which is an antineoplastic alkylating agent. Treanda is indicated for patients with: 1. Relapsed indolent B-cell non-Hodgkin lymphoma (NHL) who did not respond to or progressed during or shortly following treatment with a rituximab regimen; or 2. Symptomatic chronic lymphocytic leukaemia (CLL) who have received no prior treatment. Read more here.
No comments:
Post a Comment